QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform
– Agreement will initially cowl the UK and France with potential to increase to different European nations and worldwide
NEWCASTLE UPON TYNE, UK and FLORENCE, 2 November 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), are happy to announce an unique distribution settlement for QuantuMDx’s Q-POC™ platform within the UK and France.
Under the phrases of the settlement, Menarini will market, promote and service Q-POC™, QuantuMDx’s SARS- CoV-2 assay and its new SARS-CoV-2, Flu A/B, RSV Respiratory Panel check which the Company launched earlier this yr. The five-year settlement will initially cowl distribution to the UK and France, with the scope to increase to different markets.
Jonathan O’Halloran, Chief Executive Officer, QuantuMDx, stated: “This agreement with Menarini is a significant commercial step for QuantuMDx. Not only does Menarini have a vast global network, but their specific in-country knowledge and presence across Europe, and beyond, means they are an excellent partner for us. The agreement will allow us to further accelerate commercial sales of Q- POC™, bringing our Point-of-Need multiplex molecular diagnostics platform to clinical and non-clinical settings in a host of new markets. I look forward to working closely with Menarini on what I am confident will be a very successful partnership.”
Fabio Piazzalunga, Global Head, Menarini Diagnostics S.r.I., commented: “The recent pandemic has highlighted the importance of being able to accurately, and rapidly, diagnose infectious diseases. QuantuMDx’s Q-POC™ platform, which can provide results in approximately 30 minutes, will allow healthcare professionals to make informed treatment decisions and slow the risk of transmission. Menarini is a pioneer in decentralising diagnostics routines and developed core competencies and technologies in doing so. We are extremely happy to be able to start providing such an innovative platform to laboratories in the UK and France.”
###
Notes to editor:
About QuantuMDx
QuantuMDx is a progressive MedTech firm enthusiastic about empowering the world to manage illness and cut back struggling. QuantuMDx solves real-world diagnostic issues by creating multiplex molecular options for the Point-of-Need.
QuantuMDx has world operations and strategic partnerships – holding it on the forefront of molecular diagnostics.
Q-POC™ is a speedy, easy to make use of, moveable, pattern to reply multiplex PCR machine. It has been designed to be used in a spread of real-world healthcare settings.
Q-POC™ and its first check, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked below the In Vitro Diagnostics Directive (98/79/EC), enabling use throughout the European Union and the UK. On twenty sixth May Q-POC was CE marked below the IVDR (Regulation EU 2017/746).
QuantuMDx plans to launch a spread of syndromic multiplex testing assays over the approaching months and years.
For extra details about QuantuMDx and Q-POC™, its speedy PCR level of care system, go to: www.quantumdx.com.
About A.Menarini Diagnostics, the Human Touch of Technology:
The firm has greater than 45 years devoted to serving to healthcare professionals make secure and sustainable prognosis, enhancing the standard of life of individuals all around the world.
A.Menarini Diagnostics is a part of the Menarini Pharmaceutical Group, based in 1886. Today it’s current in 140 nations all through the world, it counts greater than 17,000 workers and has a 2020 turnover of € 3.750 billion.
Find out extra: www.menarinidiagnostics.com
For media enquiries and interview requests:
Tracey Cadman , Marketing Communications Manager, QuantuMDx, M: +44 (0) 7495 341 931 T: +44
(0) 870 803 1234 E: [email protected]
Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications,
+44 (0)20 3709 5700 / quantumdx@consilium-comms.com
Menarini Group, [email protected], +39 055 56801
For investor enquiries:
David Wilson, Nigel Barnes and Robin Sturken, WG Partners (Financial Adviser to QuantuMDx),
+44 (0)20 3705 9330 / [email protected]
